Publication:
Evaluation of anti-glioma effects of benzothiazoles as efficient apoptosis inducers and DNA cleaving agents

dc.contributor.coauthorSever, Belgin
dc.contributor.kuauthorÇiftçi, Halil İbrahim
dc.date.accessioned2024-11-09T23:30:26Z
dc.description.abstractGlioma is the fast-growing, aggressive, and prevalent brain cancer with a great level of morbidity and mortality. Current therapy is usually found insufficient for glioma treatment. In the course of our research attempting to identify effective anti-glioma agents, three benzothiazole derivatives (1-3) were examined on U251 glioma cells. Among these derivatives, compound 3 was found to have the strongest cytotoxic effect on glioma cells with an IC50 value of 9.84 +/- 0.64 mu M in reference to cisplatin (IC50 = 8.41 +/- 1.27 mu M). Further mechanism of anti-glioma effects of compound 3 was characterized by the determination of its apoptotic effects in glioma cells and DNA cleaving capacity. Compound 3 caused a significant apoptotic death of U251 cell line. Besides, this compound cleaved DNA with FeSO4, H2O2 and ascorbic acid system. Molecular docking results also showed that compound 3 possessed a significant binding potential to DNA via important pi-pi stacking interaction with DG-16. Some pharmacokinetic determinants of compound 3 complied with standard limits making it as an efficient bioavailable anti-glioma drug candidate for upcoming exploration.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipAnadolu University Scientific Research Projects Commission [2105S050]
dc.description.sponsorshipTUBITAK[121C063] This research was supported by Anadolu University Scientific Research Projects Commission with Grant No. 2105S050 and by TUBITAKunder 2236 CoCirculation2 program with Grant No. 121C063. The entire responsibility of the publication belongs to the authors. The financial support received from TUBITAKdoes not mean that the content of the publication is approved in a scientific sense by TUBITAK.
dc.identifier.doi10.1007/s11010-022-04580-4
dc.identifier.eissn1573-4919
dc.identifier.issn0300-8177
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85139682394
dc.identifier.urihttps://doi.org/10.1007/s11010-022-04580-4
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12239
dc.identifier.wos865926700006
dc.keywordsBenzothiazole
dc.keywordsGlioma
dc.keywordsApoptosis
dc.keywordsDNA cleavage activity
dc.keywordsMolecular docking studies blood-brain-barrier
dc.keywordsGlioma-cells
dc.keywordsIn-vitro
dc.keywordsC6
dc.keywordsGrowth
dc.keywordsDerivatives
dc.keywordsDamage
dc.keywordsAssay
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofMolecular and Cellular Biochemistry
dc.subjectCell biology
dc.titleEvaluation of anti-glioma effects of benzothiazoles as efficient apoptosis inducers and DNA cleaving agents
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorÇiftçi, Halil İbrahim

Files